The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: The NOCTE study

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 3, 2010, Pages 369-377

  Cooper, Vanessa ^a   Horne, Rob ^a   Gellaitry, Grace ^a   Vrijens, Bernard ^b,c   Lange, Anne Catherine ^b   Fisher, Martin ^d   White, David ^e  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Pharmionic Research Centre   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UK   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; EVENING DOSAGE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CULTURE; DIDANOSINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUESTIONNAIRES; ZIDOVUDINE;

EID: 77649207549     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ccb762     Document Type: Article

References (55)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
2. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
3. Gross R, Yip B, Wood E. et al. Boosted PI are more forgiving of suboptimal adherence than non-boosted PI or NNRTI. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; Februay 5-8, 2006; Denver, Colorado.
4. Molina JM, Journot V, Furco A, et al. Five-year follow-up of once daily HAART with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial). Antivir Ther. 2007;12:417-422.
5. Johnson MA, Gathe JC, Podzamczer D, et al. A once-daily lopinavir/ ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43: 153-160.
6. Santos J, Palacios R, Lopez M, et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine and efavirenz in naive patients: the VESD study. HIV Clin Trials. 2005;6:320-328.
7. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8:339-346.
8. Moyle G. The assessing patients' preferred treatments (APPT-1) study. Int J STD AIDS. 2003;14(Suppl 1):34-36.
9. Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence with once-daily anti-retroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48: 484-488.
10. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. Zidovudine, lamivudine and efavirenz for HIV. N Eng J Med. 2006;354:251-260.
11. Cooper V, Horne R, Fisher M, et al, The SWEET study group. "Simplification with easier emtricitabine and tenofovir (SWEET): results of a 48 week analysis of patients' perceptions of treatment and adherence", Poster presentation at: The XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
12. Stone V, Hogan J, Schuman P, et al. ARV regimen complexity, self-reported adherence and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001; 28:124-131.
13. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 28:47-58.
14. Aversa SL, Kimberlin C. Psychosocial aspects of antiretroviral medication use among HIV patients. Patient Educ Couns. 1996;29:219.
15. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
16. Gebo KA, Keruly J, Moore RD. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med. 2003;18:104-111.
17. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38-45.
18. Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.
19. Chesney M, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care. 2000;12:255-266.
20. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr. 1998;18:117-125.
21. Molassiotis A, Nahas-Lopez V, Chung WY, et al. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002;13:301-310.
22. Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care. 2000;12:377-386.
23. Sankar A, Luborsky M, Schuman P, et al. Adherence discourse among African-American women taking HAART. AIDS Care. 2002;14:203.
24. Horne R. Treatment perceptions and self regulation. In: Cameron LD, Leventhal H, eds. The Self-Regulation of Health and Illness Behaviour. London, United Kingdom: Routledge; 2003.
25. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1-24.
26. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555-567.
27. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;14:1-24.
28. Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15:38-44.
29. Horne R, Cooper V, Gellaitry G, et al. Patients' perceptions of highly active anti-retroviral therapy (HAART) in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007;45:334-341.
30. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database of Syst Rev. 2009;Issue 2. CD00001.
31. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother. 2005;55:616-627.
32. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-1117.
33. Cooper V, Buick D, Horne R, et al. Perceptions of HAART among gay men who declined a treatment offer: preliminary results from an interview-based study. AIDS Care. 2002;14:319-328.
34. Newell A, Mendes da Costa S, Horne R. Assessing the psychological and therapy-related barriers to optimal adherence: an observational study. Presented at: Sixth International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, United Kingdom.
35. Blaschke TF. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes. Curr Opin HIV AIDS. 2008;3: 603-607.
36. Comté L, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BiD dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007;34:549-558.
37. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38: 1311-1316.
38. Ruane P, Lang J, Dejesus E. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. Int J Infect Dis. 2005;9:195-200.
39. Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6:185-190.
40. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22:1951-1960.
41. Molina JM, Podsadecki TJ, Johnson MA. et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505-1514.
42. Kleeburger CA, Phair JP, Strathdee, SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.
43. Gonzalez J, Penedo F, Llabre M, et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34:46-55.
44. Horne R, Cooper V, Gellaitry G, et al. Identifying the key beliefs influencing uptake and adherence to HAART: Final results of a 12 month, prospective, follow-up study. 11th Annual Conference of the British HIV Association [BHIVA] and the British Association for Sexual Health and HIV [BASHH]. April 20-23, 2005; Dublin, Ireland.
45. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
46. Cooper V, Gellaitry G, Hankins M, et al. The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six month prospective, follow-up study. AIDS Care. 2009;21:520-528.
47. Mannheimer S, Thackeray L, Hullsiek KH, et al. A randomised comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20:161-169.
48. Dlamini PS, Wantland D, Makoae LN. HIV stigma and missed doses in HIV positive people in five African countries. AIDS Patient Care STDS. 2009;23:377-387.
49. Elford E, Ibrahim F, Bukutu C. et al. Disclosure of HIV status: the role of ethnicity among people living with HIV in London. J Acquir Immune Defic Syndr. 2008;47:514-521.
50. Gatti ME, Jacobson KL, Gazmararian JA, et al. Relationships between beliefs about medicines and adherence. Am J Health Sys Pharm. 2009;66: 657-664.
51. Wrubel J, Stumbo S, Johnson MO. Antiretroviral medication support among partners of men who have sex with men: a qualitative study. AIDS Patient Care STDS. 2008;22:851-858.
52. Gazzard BG; BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine. 2008;9:563-608.
53. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
54. El-Sadr WM, Grund B, Neuhaus J, et al. Risk of opportunistic disease and death after re-initiating antiretroviral therapy in patients previously receiving episodic therapy: a randomised trial. Ann Intern Med. 2008;149: 289-299.
55. Horne R, Weinman J, Barber N, et al. Concordance, Adherence and Compliance in Medicine Taking: A conceptual Map and Research priorities. London, United Kingdom: National Institute for Health Research (NIHR) Service Delivery and Organisation (SDO) Programme; 2006. Available at: http://www.sdo.lshtm.ac. uk/sdo762004.html. Accessed June 10, 2008.